# Ozempic and Wegovy Before and After: What the Trial Averages Would Look Like

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-11-16

Canonical page: https://glpwatchdog.org/research/semaglutide-before-and-after

> No photos here. Trial numbers show the typical result: on Wegovy 2.4 mg, an average 14.9% loss and 13.5 cm off the waist at 68 weeks, with about 30% losing a fifth of their weight. Ozempic's diabetes-trial losses were smaller. How to read a before-and-after photo.

## Key points

- In STEP 1, people on Wegovy 2.4 mg lost an average 14.9%, or 15.3 kg, and 13.5 cm off the waist at 68 weeks.
- The label shows 83.5% lost at least 5%, 47.9% at least 15% and 30.2% at least 20%.
- On placebo, 4.8% lost at least 15%, so a dramatic photo does not show that a drug caused the result.
- Ozempic's diabetes trials recorded average losses of 5.5 kg at 1 mg over 56 weeks and 6.4 kg at 2 mg over 40 weeks.
- Real-world figures near the trial results mostly count people who stayed on treatment. A broad health-record cohort averaged 10.8%.

A typical Wegovy before-and-after, going by the main trial, is someone starting near 232 lb who is about 34 lb lighter and 5 inches smaller at the waist after 68 weeks, an average loss of **14.9%**.[1][2] About 30% lost a fifth or more of their weight and about 16% lost under 5%, so the dramatic photos in ads show the top of that range.[1] Ozempic, the diabetes version, was tested at lower doses and in people with diabetes, and its numbers are smaller.[3]

> **About this article.** This page has no photos because we have none we could verify, and it does not simulate any. It reports what trials measured at set times. The stage-by-stage curve and what happens after stopping are in the [semaglutide results timeline](https://glpwatchdog.org/research/semaglutide-results-timeline), and the Zepbound and Mounjaro equivalent is tirzepatide before and after.

## What would the average Wegovy before and after look like?

STEP 1 put 1,961 adults without diabetes on semaglutide 2.4 mg or placebo for 68 weeks, both alongside a lifestyle program.[2] The average treated participant started at 105.4 kg and lost 15.3 kg, while the waist shrank by 13.5 cm against 4.1 cm on placebo.[1][2] In everyday units that is about 34 lb and 5.3 inches.

*Semaglutide 2.4 mg at set time points, drug vs placebo. All figures are group averages.*

| When | Who | Weight change | Waist change |
| --- | --- | --- | --- |
| 68 weeks, STEP 1[1] | Overweight or obesity, no diabetes | −14.9% vs −2.4% | −13.5 cm vs −4.1 cm |
| 68 weeks, STEP 3[1] | Same, with intensive lifestyle therapy | −16% vs −5.7% | −14.6 cm vs −6.3 cm |
| 68 weeks, STEP 2[1][4] | Overweight or obesity with type 2 diabetes | −9.6% vs −3.4% | −9.4 cm vs −4.5 cm |
| 104 weeks, STEP 5[5] | Overweight or obesity, no diabetes | −15.2% vs −2.6% | Not in the abstract |
| 208 weeks, SELECT[6] | Heart disease with overweight or obesity, no diabetes | −10.2% vs −1.5% | −7.7 cm vs −1.3 cm |

Compare trials with care. SELECT enrolled a different population, so its smaller four-year figure does not mean weight came back; the paper describes the loss as sustained over four years.[6] A higher 7.2 mg dose now exists, and [what the 7.2 mg dose costs](https://glpwatchdog.org/research/wegovy-7-2-mg-what-it-costs) covers that trade. How much a person with diabetes can expect is a separate figure as well, as the STEP 2 row shows.

## What is the range between typical and best-case results?

The spread matters more than the average for anyone looking at a photo. The Wegovy label reports what share of each group crossed each threshold at week 68, and those shares are what a fair gallery of before-and-after pictures would reflect.[1]

*Share of people reaching each weight-loss threshold at week 68 in STEP 1, from the Wegovy label. Pounds assume the 105.4 kg (232 lb) average start.*

| Lost at least | About | Wegovy 2.4 mg | Placebo |
| --- | --- | --- | --- |
| 5% | 12 lb | 83.5% | 31.1% |
| 10% | 23 lb | 66.1% | 12% |
| 15% | 35 lb | 47.9% | 4.8% |
| 20% | 46 lb | 30.2% | 1.7% |

Three things stand out. About one person in six on the drug did not reach 5%. Fewer than half reached 15%, which is close to the headline average. And the placebo column is not empty: about one person in twenty on a lifestyle program and a dummy injection lost 15% or more.[1] A striking photo, on its own, does not show which column its subject belongs in.

The published paper gives slightly higher shares for the same trial (86.4%, 69.1% and 50.5% at the first three thresholds) because it handled missing data differently.[2] A review of subgroups found women lost more than men, which [who loses more weight on a GLP-1](https://glpwatchdog.org/research/who-loses-more-weight-on-a-glp1) explains along with why most other subgroup differences did not appear.

## Ozempic before and after: why the numbers differ from Wegovy

Many photos labeled “Ozempic” show someone using it off label. Ozempic and Wegovy contain the same molecule, but Ozempic’s labeled uses are blood sugar control and lowering cardiovascular and kidney risk in adults with type 2 diabetes, and it comes in lower doses.[3] Its trials also measured weight, as a side result:

- **Ozempic 1 mg, 56 weeks:** an average of 5.5 kg (about 12 lb) lost, from 89.2 kg.[3]
- **Ozempic 2 mg, 40 weeks:** an average of 6.4 kg (about 14 lb) lost, from 100.1 kg.[3]
- **Semaglutide 2.4 mg with diabetes, 68 weeks:** −9.6% against −3.4% on placebo, and 12.8% lost a fifth of their weight, compared with 30.2% of people without diabetes.[1]

So a person with diabetes on Ozempic comparing themselves to a Wegovy photo is comparing against a different dose, a different population and a different length of treatment. Our [Wegovy vs Ozempic comparison](https://glpwatchdog.org/compare/drugs/wegovy-vs-ozempic) sets the two side by side.

## Do real-world results match the trials?

They can, for people who stay on treatment at a full dose, but those studies leave many others out.

*Semaglutide outcomes outside trials. All are retrospective, and each chose its patients differently.*

| Study | Who was counted | Result |
| --- | --- | --- |
| SHAPE, 2025[8] | 6,794 US patients with no gap over 30 days' supply for a year | −14.1% at 1 year |
| SCOPE, 2025[7] | Patients who reached and stayed on 1.7 or 2.4 mg; 175 had a 24-month weight | −16.6% at 24 months |
| Samuels, 2025[10] | Clinic patients at no cost, on semaglutide or tirzepatide, persistent for 12 months | Median −14.4%; middle half 9.5% to 20.5% |
| Venkatakrishnan, 2026[9] | 10,339 semaglutide patients in matched health records | Mean loss 10.8%; 21.6% reached 15% in year one |

The last row is the broadest and the least flattering, and the first three count only people who kept going. Plenty do not: among 288 people who stopped semaglutide or tirzepatide within a year in one health system, 47.6% cited cost or insurance, 14.6% side effects and 11.8% shortages, while only 1.7% cited unsatisfactory weight loss.[19] A final-result photo comes from someone who stayed the course, and many others could not.

## What changes besides the number on the scale?

**Fat and muscle.** Some of the weight lost is not fat. A 2026 meta-analysis put lean mass at 35.2% of the weight lost on semaglutide, while finding the share broadly comparable to lifestyle weight loss overall.[11] A 2026 systematic review found a median of 28.3% across incretin drugs and noted that no study in it reported objective physical function.[12] In an MRI analysis of 55 people from the STEP UP trial, most of them on the higher 7.2 mg dose, fat tissue fell by 11.1 L compared with placebo and thigh muscle by 1.1 L, a difference that was not statistically significant.[13]

**Face and skin.** We did not find facial outcomes reported in these trial sources, and the labels do not list them. The closest measurement is a scan study of 20 GLP-1 users that found about 7% of [midface volume](https://glpwatchdog.org/research/ozempic-face-what-the-studies-measured) lost per 10 kg.[14] A 2026 review links rapid loss, older age and low protein intake with worse skin changes.[15]

**Hair.** Pooling three trials, the label records hair loss as an adverse reaction in 3.3% on Wegovy 2.4 mg, with women far more affected than men (4% and 0.9%), and in 1% on placebo. It ties the problem to weight reduction.[1]

## How can you tell if a before-and-after photo is real or typical?

You usually cannot verify one from outside, but you can check how much it tells you. A 2026 analysis of semaglutide content on social media judged that weight-loss result videos have a high probability of AI modification, and [what Instagram leaves out](https://glpwatchdog.org/research/what-instagram-leaves-out) covers that study.[16] Run any picture through these questions:

- **How long, at what dose, on what product?** A photo with no dates cannot be compared with a 68-week figure, and a compounded product has no trial data of its own behind it, as [compounded versus brand semaglutide](https://glpwatchdog.org/research/compounded-semaglutide-vs-brand-semaglutide) explains.
- **Is it the top of the range?** About 30% of trial participants lost a fifth of their weight, and a seller can fill a gallery from them alone.[1]
- **Are the two pictures comparable?** Lighting, posture, angle and clothing all change how a body looks. Surgeons drawing up standards for their own field agreed on the same body position and on showing average outcomes; weight-loss ads have no such standard.[18]
- **What else changed?** A person may have changed their diet, added training or had surgery, and the placebo column shows how far that alone can go.[1]
- **Does the ad imply this is normal?** Under FTC guides, an ad using a consumer’s experience will likely be read as showing what buyers will generally achieve. The advertiser should be able to back that up, and a small “results not typical” style disclaimer may not cure it.[17]

Real photos from real patients are not worthless. They show one person’s result, and they cannot show what the same drug will do for you. For a realistic expectation, use the threshold table above.

## Frequently asked questions

### How much weight do people lose on Wegovy before and after?

In the 68-week STEP 1 trial the average was 14.9%, or 15.3 kg (about 34 lb) from an average start of 105.4 kg, with the waist down 13.5 cm. On placebo the average loss was 2.4%. About 30% on the drug lost at least a fifth of their weight, and about 16% lost under 5%.

### What does Ozempic do to your body before and after?

In Ozempic’s diabetes trials, average weight loss was 5.5 kg at 1 mg over 56 weeks and 6.4 kg at 2 mg over 40 weeks, alongside lower blood sugar. Ozempic is not labeled for weight loss. Larger losses in photos usually reflect a person at the top of the range or a higher-dose product such as Wegovy.

### How long before you see results on semaglutide?

Weight falls during the dose increases, and the largest average figures come after more than a year. In STEP 1 the endpoint was 68 weeks, and in STEP 5 the average at two years was 15.2%. A photo taken at three months is not comparable with those figures.

### Are semaglutide before-and-after photos real?

Some are and some may not be, and a viewer usually cannot tell. A 2026 analysis judged that social media weight-loss videos have a high probability of AI modification. Even a real photo shows one person, so check the dates, the dose and what else changed, and compare it with the trial ranges.

### Will my face or skin change on semaglutide?

It may, in proportion to weight lost. A scan study of 20 GLP-1 users found about 7% of midface volume lost per 10 kg, mostly from superficial fat, though it had no comparison group. The Wegovy label records hair loss in 3.3% of people on 2.4 mg and 1% on placebo.

## References

1. Novo Nordisk WEGOVY (semaglutide) prescribing information. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. PMID: 33567185. DOI: 10.1056/NEJMoa2032183. https://pubmed.ncbi.nlm.nih.gov/33567185/
3. Novo Nordisk OZEMPIC (semaglutide) prescribing information. DailyMed, U.S. National Library of Medicine. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
4. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021. PMID: 33667417. DOI: 10.1016/S0140-6736(21)00213-0. https://pubmed.ncbi.nlm.nih.gov/33667417/
5. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022. PMID: 36216945. DOI: 10.1038/s41591-022-02026-4. https://pubmed.ncbi.nlm.nih.gov/36216945/
6. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine. 2024. PMID: 38740993. DOI: 10.1038/s41591-024-02996-7. https://pubmed.ncbi.nlm.nih.gov/38740993/
7. Ruseva A, Michalak W, Fabricatore A, et al. Sustained weight reduction with once-weekly semaglutide: results from a real-world retrospective cohort study in the United States (SCOPE 24 months). Current Medical Research and Opinion. 2025. PMID: 41351543. DOI: 10.1080/03007995.2025.2591464. https://pubmed.ncbi.nlm.nih.gov/41351543/
8. Ng CD, Divino V, Wang J, et al. Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE). Advances in Therapy. 2025. PMID: 40875186. DOI: 10.1007/s12325-025-03340-2. https://pubmed.ncbi.nlm.nih.gov/40875186/
9. Venkatakrishnan AJ, Murugadoss K, Soundararajan V, et al. Weight-loss dynamics with tirzepatide versus semaglutide. PNAS Nexus. 2026. PMID: 42311474. DOI: 10.1093/pnasnexus/pgag171. https://pubmed.ncbi.nlm.nih.gov/42311474/
10. Samuels JM, Ye F, Irlmeier R, et al. Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic. Diabetes, Obesity and Metabolism. 2025. PMID: 40762026. DOI: 10.1111/dom.70004. https://pubmed.ncbi.nlm.nih.gov/40762026/
11. Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Diabetes, Obesity and Metabolism. 2026. PMID: 41877354. DOI: 10.1111/dom.70666. https://pubmed.ncbi.nlm.nih.gov/41877354/
12. Batsis JA, Gavras A, Gross DC, et al. Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition: A Systematic Review. Annals of Internal Medicine. 2026. PMID: 41996180. DOI: 10.7326/ANNALS-25-00478. https://pubmed.ncbi.nlm.nih.gov/41996180/
13. Hjelmesæth J, Bhat S, Garvey WT, et al. Effect of Semaglutide on Thigh Skeletal Muscle Volume, Fat Infiltration and Physical Function in People With Obesity: Secondary Analysis of STEP UP. Diabetes, Obesity and Metabolism. 2026. PMID: 42764399. DOI: 10.1111/dom.71323. https://pubmed.ncbi.nlm.nih.gov/42764399/
14. Sharma RK, Vittetoe KL, Barna AJ, et al. Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists. Otolaryngology–Head and Neck Surgery. 2025. PMID: 40407186. DOI: 10.1002/ohn.1209. https://pubmed.ncbi.nlm.nih.gov/40407186/
15. Barone M, Brunetti B, D'Emilio R, et al. Effects of GLP-1 Receptor Agonists on Skin Quality: A Comprehensive Literature Review. Aesthetic Plastic Surgery. 2026. PMID: 42162206. DOI: 10.1007/s00266-026-05820-4. https://pubmed.ncbi.nlm.nih.gov/42162206/
16. Propfe LE, Seifert R. Misrepresentation of semaglutide in social media. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. PMID: 40682686. DOI: 10.1007/s00210-025-04403-5. https://pubmed.ncbi.nlm.nih.gov/40682686/
17. Federal Trade Commission 16 CFR 255.2, Consumer endorsements (Guides Concerning the Use of Endorsements and Testimonials in Advertising). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/cfr/text/16/255.2
18. Valiquette CR, Forrest CR, Kasrai L, et al. Can We Reach a Consensus on the Appropriate Use of Before and After Photos in Breast Surgery?. Plastic and Reconstructive Surgery Global Open. 2021. PMID: 34285856. DOI: 10.1097/GOX.0000000000003682. https://pubmed.ncbi.nlm.nih.gov/34285856/
19. Gasoyan H, Butsch WS, Casacchia NJ, et al. Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice. Obesity. 2025. PMID: 41039650. DOI: 10.1002/oby.70058. https://pubmed.ncbi.nlm.nih.gov/41039650/

---

Cite as: GLP Watchdog, Ruth Calder, "Ozempic and Wegovy Before and After: What the Trial Averages Would Look Like", published 2026-11-16. https://glpwatchdog.org/research/semaglutide-before-and-after

Canonical HTML page: https://glpwatchdog.org/research/semaglutide-before-and-after

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
